Pandemic Darlings The pandemic economy, in original documents
Home Source documents Sorrento Therapeutics, Inc. Form 4 (Sept. 7, 2022)Search ⌕

Sorrento Therapeutics, Inc. Form 4 (Sept. 7, 2022)

Summary

A Form 4 for Henry Ji, a director and officer of Sorrento Therapeutics, Inc. [SRNE] whose remarks list the title President, CEO and Chairman of the Board of Directors, reporting purchases on September 7, 2022. Ji bought 88,888 shares of common stock at a weighted average price of $2.0177, in transactions at prices ranging from $2.01 to $2.02, inclusive, bringing directly owned shares to 4,765,805. The form also reports purchases of 759 call options at $40.66 and 129 call options at $41.66, each with a $12 exercise price and expiring 01/19/2024, attributed to BioVintage, Inc. It lists 2,271,693 shares owned in family trusts of which the reporting person is a co-trustee. The form is signed /s/ Henry Ji, Ph.D. on 09/07/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Sorrento Therapeutics, Inc. Form 4 (Sept. 7, 2022).” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-srne-4-filed2022-09-07-0001209191-22-049065-839c3e6ccd/, SHA-256 6d898ecc5e4d45462473894f1d7943935a8e0870d2218bfa802171bd5ced29b4.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Ji Henry (Last) (First) (Middle) C/O SORRENTO THERAPEUTICS, INC. 4955 DIRECTORS PLACE (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | Ji Henry | (Last) | (First) | (Middle) | C/O SORRENTO THERAPEUTICS, INC. | 4955 DIRECTORS PLACE | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Sorrento Therapeutics, Inc. [ SRNE ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) See Remarks | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | See Remarks
3. Date of Earliest Transaction
 (Month/Day/Year) 09/07/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 09/07/2022 | P | 88,888 | A | $ 2.0177 (1) | 4,765,805 | D
Common Stock | 2,271,693 | I | See Footnote (2)
Common Stock | 40,000 | I | By spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Call Option (right to buy) | $ 12 | 09/07/2022 | P | 759 | 09/07/2022 | 01/19/2024 | Common Stock | 75,900 | $ 40.66 | 759 | I | By BioVintage, Inc.
Call Option (right to buy) | $ 12 | 09/07/2022 | P | 129 | 09/07/2022 | 01/19/2024 | Common Stock | 12,900 | $ 41.66 | 129 | I | By BioVintage, Inc.
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.01 to $2.02, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
2. Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.
Remarks:
President, CEO and Chairman of the Board of Directors
/s/ Henry Ji, Ph.D. | 09/07/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_SRNE_4_filed2022-09-07_0001209191-22-049065.xml
Size
18,633 bytes
SHA-256
6d898ecc5e4d45462473894f1d7943935a8e0870d2218bfa802171bd5ced29b4
Our copy
SEC_SRNE_4_filed2022-09-07_0001209191-22-049065.xml
Original
www.sec.gov
Back to top